Valuation: Incyte Corporation

Market Cap 24.85B 22.28B 20.53B 18.65B 35.29B 2,329B 36.28B 246B 97.96B 1,248B 93.24B 91.26B 3,945B P/E 2026 *
58.4x
P/E 2027 * 17.3x
Enterprise Value 20.55B 18.43B 16.99B 15.43B 29.19B 1,927B 30.01B 203B 81.03B 1,032B 77.13B 75.49B 3,264B EV / Sales 2026 *
3.4x
EV / Sales 2027 * 3.02x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.30%
1 week+2.30%
Current month-0.07%
1 month+8.03%
3 months-1.03%
6 months+19.92%
Current year+21.80%
1 week 115
Extreme 115
123.96
1 month 107.78
Extreme 107.7801
123.96
Current year 89.25
Extreme 89.25
132.6
1 year 89.25
Extreme 89.25
132.6
3 years 50.35
Extreme 50.3498
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Principal Accounting Officer

-610 0.0003%
15/10/26 Exercice

Chairperson

7,926 0.0039%
01/10/26 Tax

EVP, Head of Incyte Intl

-463 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+2.30%+13.51%+129.41% 24.85B
+1.44%+1.63%+48.17%+139.63% 1,258B
-0.47%+5.49%+49.03%+90.68% 679B
+0.20%+2.76%+34.37%+112.06% 518B
+0.17%+1.16%+49.70%+68.75% 390B
-0.48%+2.34%+70.66%+46.02% 367B
+0.76%+2.25%+31.84%+59.53% 307B
-1.29%+0.17%+7.63%+33.04% 293B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 210B
Average +0.08%+0.88%+39.33%+87.82% 430B
Weighted average by Cap. +0.42%+1.16%+44.14%+96.56%

Financials

2026 *2027 *
Net sales 6.05B 5.43B 5B 4.54B 8.6B 568B 8.84B 59.9B 23.87B 304B 22.72B 22.24B 961B 6.31B 5.66B 5.21B 4.74B 8.96B 592B 9.21B 62.43B 24.87B 317B 23.68B 23.17B 1,002B
Net income 432M 388M 357M 324M 614M 40.53B 631M 4.28B 1.7B 21.72B 1.62B 1.59B 68.65B 1.45B 1.3B 1.2B 1.09B 2.07B 136B 2.12B 14.4B 5.74B 73.08B 5.46B 5.34B 231B
Net Debt -4.29B -3.85B -3.55B -3.22B -6.1B -403B -6.27B -42.49B -16.93B -216B -16.11B -15.77B -682B -5.82B -5.22B -4.81B -4.37B -8.27B -546B -8.5B -57.59B -22.95B -292B -21.84B -21.38B -924B
Projected Income Statement - Annual - Incyte Corporation
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
11/11/26 $120.30 -1.30% 1,797,798
09/11/26 $121.89 +1.87% 1,154,647
06/11/26 $119.65 +1.39% 1,486,482
05/11/26 $118.01 -3.94% 1,600,119
04/11/26 $122.85 +4.47% 2,140,862
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Incyte Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
121.89USD
Average target price
131.50USD
Spread / Average Target
+7.88%
  1. Stock Market
  2. Stocks
  3. INCY Stock